

Gisela Barbany

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8705770/publications.pdf>

Version: 2024-02-01

35
papers

864
citations

840776

11
h-index

477307

29
g-index

35
all docs

35
docs citations

35
times ranked

1812
citing authors

#	ARTICLE	IF	CITATIONS
1	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	16.8	292
2	The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2015, 47, 672-676.	21.4	147
3	DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia. <i>Clinical Epigenetics</i> , 2015, 7, 11.	4.1	66
4	Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. <i>Blood Advances</i> , 2019, 3, 148-157.	5.2	48
5	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. <i>Haematologica</i> , 2020, 106, 87-97.	3.5	43
6	The clinical impact of <i>IKZF1</i> deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013. <i>British Journal of Haematology</i> , 2015, 170, 847-858.	2.5	37
7	The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia. <i>Haematologica</i> , 2005, 90, 1471-6.	3.5	27
8	Quantitation of RNA decay in dried blood spots during 20 years of storage. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1467-9.	2.3	26
9	Intragenic amplification of PAX5: a novel subgroup in B-cell precursor acute lymphoblastic leukemia?. <i>Blood Advances</i> , 2017, 1, 1473-1477.	5.2	25
10	Successful pregnancies after transplantation of ovarian tissue retrieved and cryopreserved at time of childhood acute lymphoblastic leukemia – A case report. <i>Haematologica</i> , 2021, 106, 2783-2787.	3.5	24
11	Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4030-4038.	7.0	20
12	A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias. <i>Frontiers in Medicine</i> , 2022, 9, 842507.	2.6	15
13	High-resolution detection of chromosomal rearrangements in leukemias through mate pair whole genome sequencing. <i>PLoS ONE</i> , 2018, 13, e0193928.	2.5	11
14	Detailed gene dose analysis reveals recurrent focal gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2161-2170.	1.3	10
15	Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study. <i>Lancet Haematology</i> , 2021, 8, e700-e710.	4.6	10
16	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. <i>Leukemia</i> , 2022, 36, 1834-1842.	7.2	10
17	PAX5-ESRRB is a recurrent fusion gene in B-cell precursor pediatric acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, e20-e23.	3.5	9
18	Overexpression of chromatin remodeling and tyrosine kinase genes in iAMP21-positive acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 604-613.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Increased p53 protein expression as a potential predictor of early relapse after hematopoietic stem cell transplantation in children with acute myelogenous leukemia. <i>Pediatric Transplantation</i> , 2015, 19, 767-775.	1.0	6
20	A somatic <i>UBA2</i> variant preceded <i>ETV6-RUNX1</i> in the concordant BCP-ALL of monozygotic twins. <i>Blood Advances</i> , 2022, 6, 2275-2289.	5.2	5
21	Additional aberrations of the <i>ETV6</i> and <i>RUNX1</i> genes have no prognostic impact in t(12;21)(p13;q22)-positive B-cell precursor acute lymphoblastic leukaemias treated according to the NOPHO-ALL-2000 protocol. <i>Leukemia Research</i> , 2012, 36, 936-938.	0.8	4
22	Parental origin of monosomic chromosomes in near-haploid acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 51.	6.2	4
23	Heterozygous variants in <i>DCC</i> . <i>Neurology: Genetics</i> , 2020, 6, e526.	1.9	4
24	The <i>ETV6/RUNX1</i> fusion transcript is not detected in RNA isolated from neonatal dried blood spots from children later diagnosed with the corresponding leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 2742-2744.	1.3	3
25	Strong expression of p53 protein in bone marrow samples after hematopoietic stem cell transplantation indicates risk of relapse in pediatric acute lymphoblastic leukemia patients. <i>Pediatric Transplantation</i> , 2019, 23, e13408.	1.0	2
26	Somatic Structural Alterations in Childhood Leukemia Can Be Backtracked in Neonatal Dried Blood Spots by Use of Whole-Genome Sequencing and Digital PCR. <i>Clinical Chemistry</i> , 2019, 65, 345-347.	3.2	2
27	Cytogenetic aberrations in adult acute lymphoblastic leukemia—A population-based study. <i>EJHaem</i> , 0, , .	1.0	2
28	Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38+ Stem Cell Level: Results From Randomized NordCML006 Study. <i>Blood</i> , 2011, 118, 784-784.	1.4	2
29	Multinational Study on the Clinical and Genetic Features of the ERCC6L2-Disease. <i>Blood</i> , 2021, 138, 864-864.	1.4	2
30	Nordic CML Study Group Quality and Standardization Rounds for Quantitative RT-PCR of BCR-ABL To Facilitate Reporting on the International Scale.. <i>Blood</i> , 2007, 110, 4559-4559.	1.4	1
31	Landmark Analyses of BCR-ABL Using ES-FISH Early After Start of Imatinib Treatment to Newly Diagnosed CMLcp Patients Predicts Longterm Clinical Outcome.. <i>Blood</i> , 2009, 114, 4269-4269.	1.4	0
32	The Proportion of Ph+ CD34+CD38neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study. <i>Blood</i> , 2010, 116, 667-667.	1.4	0
33	Landmark Analysis of Imatinib Treatment in CML Chronic Phase: ES-FISH <10% Ph+ At 3 Months Associated with Better Cytogenetic Response and Improved Long-Term Event-Free Survival. <i>Blood</i> , 2011, 118, 1702-1702.	1.4	0
34	Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy. <i>Blood</i> , 2013, 122, 649-649.	1.4	0
35	The Molecular Landscape of KMT2A-Rearranged Leukemia from Infancy to Adulthood Reveals Age and Leukemia-Specific Mutational Patterns. <i>Blood</i> , 2021, 138, 3479-3479.	1.4	0